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Abstract The objectives of this study are to establish
reference limits for human epididymis protein 4, HE4, and
investigate factors influencing HE4 levels in healthy
subjects. HE4 was measured in 1,591 samples from the
Nordic Reference Interval Project Bio-bank and Database
biobank, using the manual HE4 EIA (Fujirebio) for 802
samples and the Architect HE4 (Abbott) for 792 samples.
Reference limits were calculated using the statistical
software R. The influence of donor characteristics such as
age, sex, body mass index, smoking habits, and creatinine
on HE4 levels was investigated using a multivariate model.
The study showed that age is the main determinant of HE4
in healthy subjects, corresponding to 2% higher HE4 levels
at 30 years (compared to 20 years), 9% at 40 years, 20% at
50 years, 37% at 60 years, 63% at 70 years, and 101% at
80 years. HE4 levels are 29% higher in smokers than in
nonsmokers. In conclusion, HE4 levels in healthy subjects
are associated with age and smoking status. Age-dependent
reference limits are suggested.
Keywords Human epididymis protein 4.HE4.Reference
values.Epithelial cancer of the ovary
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Introduction
Ovarian cysts and tumors are commonly diagnosed in
gynecologic specialist centers. In most instances, particu-
larly in premenopausal women, these cysts and tumors are
benign and represent no threat to the health and well-being
of the patient [1]. However, the prognosis of malignant
ovarian tumors is generally poor, and ovarian cancer
remains the leading cause of death from gynecological
cancer in developed countries [2]. Several studies have
shown that primary treatment by gynecologic oncologists
specializing in the treatment of ovarian cancer provides a
survival benefit in women with ovarian cancer [3–7],
heralding the need for efficient and accurate triage of
patients with adnexal masses to appropriate treatment
centers.
In developed countries, more than 90% of ovarian
cancers are of epithelial origin. The serum tumor marker
cancer antigen 125 (CA125) is often elevated at the time of
diagnosis in patients having epithelial ovarian cancer
(EOC) [8, 9], and CA125 levels have been incorporated
in triage algorithms such as the Risk of Malignancy Index
(RMI) [10, 11].
Unfortunately, CA125 has important limitations as a
diagnostic tool. Sensitivity in stage 1 disease is less than
50%, and in some histological subtypes of EOC, such as
mucinous ovarian cancer, CA125 is only rarely elevated
[12, 13]. In terms of specificity, CA125 levels are highly
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DOI 10.1007/s13277-011-0256-4volatile in healthy subjects, particularly in premenopausal
women. Elevated levels are commonly observed in a broad
range of benign conditions, such as endometriosis and
pregnancy, and in several non-ovarian malignancies, effi-
ciently thwarting any ambitions of using the marker as a
screening tool for ovarian cancer [14]. Because of the
limitations of CA125, and the potential clinical utility of
efficient serum markers, the search for new tumor markers
for ovarian cancer continues. This pursuit has produced an
impressive number of scientific publications [15], but has
of yet not altered the approach to the patient with an
adnexal mass.
Human epididymis protein 4, HE4, has recently been
identified as a potential serum tumor marker for ovarian
cancer, used alone or in combination with CA125 [16–19].
An algorithm combining HE4, CA125, and menopausal
status, the Risk of Ovarian Malignancy Algorithm
(ROMA), has thus been shown to improve triage of patients
with pelvic tumors compared to CA125 alone and RMI
[20–22]. Although some recent studies have questioned the
predictive value of the ROMA algorithm [23, 24], there
seems to be a surge in the clinical use of HE4, either on its
own or in combination with other diagnostics. Finally,
preliminary reports suggest that HE4 may be of diagnostic
or prognostic value in other malignancies [25–27], but
further studies are probably warranted.
With any clinical test, and particularly new tumor
markers, it is important to determine its intra- and
interindividual biological variation in a reference popula-
tion. Data are already available concerning HE4 levels in
patients with benign conditions and patients with non-
ovarian malignancies, warranting optimism on behalf of
HE4 as a tumor marker [16, 28]. However, the information
about HE4 levels in the general population is still very
limited. One large study suggesting reference ranges in a
female Asian population aged 20–65 has recently been
published [29], but the lack of serum donor characteristics
somewhat limits the value of this study. In addition,
knowing that a significant proportion of women diagnosed
with ovarian cancer are of advanced age, we question the
appropriateness of completely omitting donors above
65 years of age in a study of this nature.
In the current study, we measured HE4 in 1,591
serum samples from the Nordic Reference Interval
Project Bio-bank and Database (NOBIDA) biobank
[30] from donors aged 18–86 of both sexes. The study
focus is bifold; first, we want to study the relationship
between HE4 levels and donor characteristics, such as age,
sex, body mass index, creatinine levels, smoking, fasting,
and sampling time, and second, we want to establish
appropriate reference levels for HE4. We had access to
extensive data on the donors, including age, sex, body
mass index, a range of biochemical parameters, and
smoking status, providing us with the means to identify
factors possibly affecting HE4 levels in presumably
healthy individuals.
Materials and methods
Reference samples
We obtained serum samples from the NOBIDA biobank.
Samples were partially stratified to provide a uniform age
distribution and a sufficient number of smokers. Subjects
with a previous history of a malignancy were excluded
from the study. We included 1,591 serum samples from
individuals aged 18 to 86 years, with a median age of
48 years. There were 801 women and 790 men. Weekly
alcohol consumption was recorded for 1,583 subjects to
0 units for 853 subjects, 1–21 units for 722 subjects, and
more than 21 units for 8 subjects. Smoking status was
recorded for 1,560 subjects with a daily consumption of
zero cigarettes for 1,318 subjects, one to five cigarettes for
93 subjects, and more than five cigarettes for 149 subjects.
Body mass index (BMI) data were provided for 1,584
subjects ranging from 16.5 to 43.2 with a median of 24.0.
Of the subjects, 214 reported physical activity before
sampling, 1,382 subjects reported no physical activity
before sampling, and data were lacking for 5 subjects.
Approval by the institutional review board is not required
for studies using reference samples from non-identifiable
donors obtained from external biobanks.
HE4 assays
The 1,591 serum samples were sent to us in two sets, each
set randomly taken from the NOBIDA biobank. In the first
set (802 samples), HE4 was measured using a manual HE4
enzyme immunoassay (EIA; Fujirebio Diagnostics AB,
Gothenburg, Sweden), and in the second set (789 samples),
HE4 was measured using the Architect HE4 assay (Abbott
Diagnostics, Abbott Park, IL). Samples were thawed and
mixed manually immediately prior to analysis. For the
manual assay, two control samples, L1018 (N=25), Nordic
Society of Clinical Chemistry (NFKK) Reference serum X
[30]( N=25) were included in all runs, and three control
samples (N=14) provided by Fujirebio, made from serum
pools, were included in some of the runs. Coefficients of
variation (CVs) for the control samples were 7.1%, 7.8%,
8.3%, 11.9%, and 7.4% at HE4 levels of 44.6, 46.9, 39.8,
115, and 354, respectively. For the Abbott Architect assay,
the CVs for the NFKK Reference serum X and three in
house serum pools were 3.0% (N=9), 3.4% (N=6), 3.9%
(N=7), and 5.6% (N=7) at HE4 levels of 49.5, 50.9, 102,
and 309, respectively.
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For statistical calculations, we used spreadsheets (Open-
Office Calc and MS Excel) and R 2.12.1 [31] where
appropriate. The influence of creatinine concentrations, age,
sex, physical activity, smoking and drinking habits, and
BMI was investigated prior to reference interval calcula-
tions. This was performed by log-transforming HE4,
creatinine, and BMI to yield distributions closer to
normality. The effect of categorical and continuous cova-
riates was then entered into a standard multiple linear
regression model.
Finally, we calculated reference intervals for the popu-
lation using a previously developed script in R [32]. As
samples were measured with two different methods, we
followed the principles from International Federation of
Clinical Chemistry (IFCC) [33] and Nordic Reference
Interval Project (NORIP) [34] that results were first
multiplied with a method-specific factor to yield compara-
ble results. In our case, Fujirebio results were multiplied by
0.877. Reference limits are thus given in “Abbott” units.
For the Fujirebio method, reference limits should thus be
divided with this factor (or multiplied by 1.14).
Results
Differences between manual and automated HE4 assays
Since samples were randomly assigned to either the manual
or the automated assay, we included results from both
manual and automated HE4 assays in the statistical model.
In a multivariate model including age, sex, creatinine
concentrations, BMI, smoking, alcohol consumption, and
physical activity, the manual assay was estimated to return
14.0% higher results (11.3–16.9%), which agrees fairly
well with a 12.5% difference between their medians in a
univariate model.
Statistical modeling of HE4 and covariates
We first investigated the diurnal and seasonal variation by
plotting HE4 results against the time of the day (not shown)
and month of collection (Fig. A, Electronic supplemental
materials). We did not observe any cyclical patterns by
inspection. We then plotted all variables against all
variables (ln(HE4), age of subjects, sex, smoking, alcohol
consumption, physical activity before sampling, ln(creati-
nine) concentrations, and fasting/non-fasting; Fig. B,
Electronic supplemental materials). The highest correlation
for ln(HE4) was seen between ln(HE4) and age (0.60). The
relation between ln(HE4) and age was not a straight line,
implying that age must be modeled by a higher degree
polynomial. Other strong correlations were seen between ln
(creatinine) and sex.
We thenentered dataintoa multivariatemodel,comprising
ln(HE4), age of subjects, sex, smoking, alcohol consump-
tion, physical activity before sampling, ln(creatinine)
concentrations, and fasting/non-fasting. For model selec-
tion, we used the Akaike Information Criterion (AICc)
[35]. Modeling age with a second-degree polynomial (e.g.,
Age^2) returned a lower AICc (−71.9 versus 0.4), and we
thuschosethemodelincludingthesecond-degreepolynomial.
Table A (Electronic supplement material) summarizes the
statistical model chosen.
HE4 and age
HE4 increases with increasing age, with increasing slope.
In the multivariate model, detailed above, this corresponds
to 2% higher HE4 levels at 30 years of age (compared to
20 years of age), 9% at 40 years, 20% at 50 years, 37% at
60 years, 63% at 70 years, and 101% at 80 years of age.
HE4 and smoking
In the multivariate model, HE4 is 29% higher in smokers
than in nonsmokers. From inspection (Fig. 1), one may
suspect that there is a combination of age and smoking
which might be statistically significant in a larger material
consisting of more smokers. This combination may describe
that in younger patients having a low baseline HE4, smoking
givesalargerincreaseofHE4thaninolderpatients,wherethe
baseline HE4 is higher.
HE4 and sex
The difference between sexes is relatively small, albeit it is
strongly statistically significant. Male sex is associated with
7% lower HE4 levels. However, the age-related increase in
HE4 is more pronounced in men (Figs. 2 and 3), so young
men will have lower HE4 than young women, but elderly
men will have higher HE4 than elderly women.
HE4 and BMI
High BMI is associated with lower HE4 levels,
corresponding to 5% lower HE4 at BMI of 25 (compared
to 20) and 10% lower at BMI of 30.
HE4 and creatinine
High HE4 levels are associated with higher creatinine
levels, if creatinine at 50 nmol/L is considered baseline,
creatinine at 60 nmol/L is associated with 6% higher HE4
levels, 70 nmol/L with 12% higher levels, 80 nmol/L with
Tumor Biol. (2012) 33:141–148 14317% higher levels, 90 nmol/L with 22% higher levels, and
100 nmol/L with 27% higher levels.
Proposed reference limits for HE4
Calculating reference limits for HE4 is demanding, with its
many covariates/determinants. We chose this approach: We
first adjusted results to Abbott Architect levels, excluded
subjects with active smoking, and entered results into a script,
previously developed by us [32]. We treated men and female
separately, mainly because there is presently little use of the
HE4 assay for male subjects. In calculating reference
intervals, we followed the recommendations from IFCC and
NORIPbyremovingoutliersfromthe calculation ofreference
intervals by a parametric method. Outliers were removed by
applying “Tukey’sf e n c e ” [36]. In this context, subjects
having a result (after results were transformed to a Gaussian
distribution) more than 1.5 times the interquartile range (the
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144 Tumor Biol. (2012) 33:141–148difference between the 75th and 25th percentiles) outside the
25th or 75th percentile were excluded from calculations.
The proposed upper reference limits for women and men
are plotted together with the observations in Figs. 2 and 3,
respectively. HE4 increases steeply with increasing age. In
the elderly (70+), there is a relatively large subgroup of
individuals with high HE4 outside the distribution. The
detailed reference limits for both sexes are given in Table 1.
Discussion
HE4 levels in normal subjects
Although HE4 is a human epididymis protein, and
proposed as a marker of ovarian cancer, differences
between sexes are small, suggestive that the main source
of HE4 in healthy individuals may not be related to the
reproductive organs. We did not look for patterns attribut-
able to the female menstrual cycle, but given the rather
small residual variance in the study and relatively low HE4
levels in younger women, such a factor must be small. A
recent publication in Tumor Biology describes a modest, but
potentially important, variation in HE4 levels between the
different phases of the female menstrual cycle [37]. HE4
levels seem not to be affected by time of sampling, fasting,
exercise, or seasonal factors.
We have identifiedtwo maindeterminantsofHE4 levelsin
healthy individuals. The first determinant is smoking, and
particularly in younger subjects, active smoking is related to a
clear increase in HE4 levels. We have previously noted an
increase in carcinoembryonic antigen (CEA) levels and a
decrease in NSE levels in active smokers [38]. The
mechanism behind elevated HE4 levels in smokers is
somewhat unclear. For the similar increase in CEA levels,
CEA is expressed in airway epithelium and airway inflam-
mation is likely to explain, or at least contribute to, the
elevated levels observed in smokers [39]. As HE4 is also
expressed in airway epithelium [16], inflammation might
contribute to the elevated serum levels of HE4 in active
smokers, but this remains speculative until further studies
pinpoint the association between smoking and HE4.
The second determinant is associated with age. We see a
large increase of HE4 levels in the elderly subjects.
Creatinine levels and BMI are also statistically significant,
but both creatinine levels and BMI are also significantly
associated with the age of subjects, which should warrant
caution in the interpretation. Further, the interaction
between active smoking and age is not clear-cut. We see a
tendency of a larger smoking-related increase in younger
subjects, but the absolute number of smokers is too small to
allow more extensive mathematical modeling.
We note that our proposed reference limits are markedly
lower in all age groups than the reference limit proposed in
HE4 in non-smoking men  
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Tumor Biol. (2012) 33:141–148 145the HE4 EIA kit insert (∼150 pmol/L for pre- and
postmenopausal women). Had we included smokers prior
to calculating reference limits, the contrast to the limits
suggested in the kit insert would be less dramatic. The
remaining difference could possibly be explained by
differences in size and donor characteristics of the study
populations, but this remains speculative. Our reference
limits are also markedly lower than the 95 percentiles of the
control groups in a recent publication by Molina et al. [40]
of 138 pmol/L (34 premenopausal women) and 132 pmol/L
(32 postmenopausal women), respectively. However, the
small size of the groups and the lack of (healthy) donor
characteristics make comparisons difficult. The fact that the
95 percentile among premenopausal women with benign
gynecological diseases in the Molina study is markedly
lower than in the group of healthy premenopausal controls
(77.6 pmol/L vs 138.3 pmol/L, respectively) suggests that
the control group might not be representative of healthy
women. In this respect, the 95 percentile among healthy
women (N=109) in the study by Lenhard et al. [41] are
more comparable to our reference limits. For the age groups
where comparisons are possible (below 65 years), our limits
are also comparable to the reference limit suggested in the
large study by Park et al. [29]. Interestingly, given the large
size of both study groups, the tendency of increasing HE4
levels with increasing age seen in our study population was
not found in the Korean women. Although we have no
explanation for this discrepancy, it serves as a reminder that
different populations (in this case Nordic vs Korean) can
display varying biology, both in sickness and in health. It is
quite possible that an eventual (i.e., in higher age groups)
increase in HE4 levels with increasing age also had been
identified in the Korean women had donors above 65 years
been included.
Elevated HE4 levels have been observed in patients with
renal failure [42], suggesting that HE4 (like many tumor
markers) is cleared from the circulation principally through
glomerular filtration. However, we do not know if the
reductions in glomerular filtration rate (GFR) often associ-
ated with increasing age can explain the elevated HE4
levels seen in elderly subjects in our study. This hypothet-
ical, but perhaps likely explanation is difficult to validate
since the only marker for renal function in our data,
creatinine, is rarely elevated in the early stages of kidney
disease. This is particularly true in patients with reduced
muscle mass, a common characteristic of elderly patients.
Lessons for cancer testing
There are probably two important lessons. First, any
effective algorithm for detecting cancer involving HE4
levels should include age of subjects. The relation between
age and HE4 is clearly not straight, and probably age must
be modeled with a polynomial of higher degree. A practical
consequence of our findings may be the reassessment of
previous studies. Since HE4 increases with increasing age,
and cancer risk also increases with increasing age, HE4
will, in studies where age is not included, be a pseudo-
Table 1 Suggested
age-dependent reference limits
for HE4 (picomoles per liter)
Reference limits for HE4 (pico-
moles per liter) in men and
women are given as 97.5 per-
centiles with 90% confidence
intervals. Age-dependent limits
were calculated from results
obtained with the automated
method on the Abbott Architect
platform. Smokerswereexcluded
prior to calculation
Men Women
Age Reference limit Confidence interval Reference limit Confidence interval
18 43.4 42.2 44.7 51.5 50.3 52.6
22 43.9 42.6 45.2 50.2 49.1 51.3
26 44.7 43.4 46.1 49.4 48.3 50.6
30 45.9 44.5 47.4 49.1 48.0 50.3
34 47.3 45.8 48.8 49.2 48.1 50.3
38 48.9 47.4 50.5 49.6 48.5 50.8
42 50.8 49.2 52.4 50.3 49.2 51.5
46 52.9 51.3 54.6 51.3 50.2 52.5
50 55.1 53.5 56.9 52.6 51.5 53.7
54 57.5 55.9 59.3 54.1 52.9 55.2
58 60.1 58.4 61.9 55.8 54.6 56.9
62 62.8 61.1 64.7 57.7 56.5 58.8
66 65.7 63.9 67.6 59.7 58.6 60.9
70 68.7 66.8 70.6 62.0 60.9 63.2
74 71.8 69.9 73.8 64.4 63.3 65.6
78 75.0 73.1 77.0 67.0 65.9 68.2
82 78.4 76.4 80.4 69.7 68.6 70.9
86 72.6 71.5 73.8
146 Tumor Biol. (2012) 33:141–148marker for age, and the elevated HE4 levels in cancer
subjects might thus be related more to their higher age
than to their tumors. HE4 here behaves differently from
CA125. When we made a similar study for CA125,
only minor changes in CA125 levels could be attributed
to the age of subjects [38].
Lesson two is related to smoking. Smokers have higher
levelsand a larger standarddeviation(spread).The proportion
of smokers in the study is low, but the study clearly suggests
that HE4 levels in smokers differ from nonsmokers. A
conservative approach is thus to exclude smoking subjects
when calculating and using diagnostic indices for HE4. One
should consider separate indices for smokers; however, one
must then first pinpoint the relationship between the cigarette
consumption and HE4 levels.
For future studies, we would like to evaluate the effect of
age and smoking status on the performance of the ROMA
in a clinical setting. Additionally, it could be informative to
clarify the relationship between HE4 levels and early stage
renal failure. We suggest that HE4 could be measured in a
patient population where GFR has been determined by
inulin clearance, still considered the gold standard, or novel
methods using radiotracers (
51Cr-EDTA) or contrast agents
(Iohexol). Knowledge of this relationship might be partic-
ularly important in a situation where HE4 is used in the
follow-up of cancer patients. The potential for confusion is
significant if subclinical decreases in GFR, as is often
observed with chemotherapy or increasing age, could in
itself lead to rising HE4 levels normally indicative of
treatment failure, progression or relapse of a malignant
disease.
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